AbbVie Inc. (NYSE: ABBV) closed Friday at a record $253.35, up 4.2%, marking a 52-week high and capping a remarkable rally that has added approximately $65 billion to its market capitalization since June 18. This surge is nearly six times the $10.9 billion cash consideration the company is paying to acquire Apogee Therapeutics (NASDAQ: APGE), underscoring investor confidence in AbbVie's long-term immunology pipeline despite near-term earnings dilution.
Market Performance and Valuation
The stock has climbed 17% from $216.49 on June 18, driven by robust demand for AbbVie's immunology portfolio, including Skyrizi and Rinvoq, which together generated $6.60 billion in Q1 2026, representing about 44% of total net revenue. Meanwhile, Humira sales fell 38.6% to $688 million, highlighting the urgency of AbbVie's pipeline expansion. The company raised its 2026 adjusted diluted EPS guidance to $14.08-$14.28, and the stock trades at roughly 17.9 times the midpoint of that range.
Apogee Acquisition Details
AbbVie announced the acquisition of Apogee on June 18, offering $135.11 per share in cash, a 49% premium to Apogee's closing price that day. Apogee closed Friday at $132.55, a 1.9% discount to the offer, suggesting some arbitrage opportunity. The deal is expected to reduce adjusted diluted EPS by $0.14 in 2026 and $0.46 in 2027, with the first positive contribution not anticipated until 2032. AbbVie plans to finance the transaction with debt.
Strategic Rationale and Pipeline Boost
The acquisition brings AbbVie the late-stage IL-13 antibody zumilokibart for atopic dermatitis and APG273 for asthma, bolstering its immunology and respiratory pipeline. AbbVie CEO Robert Michael emphasized the deal's potential for "creating significant long-term value for shareholders," while Apogee CEO Michael Henderson noted AbbVie's ability to "position our programs to reach their full potential." The move addresses competitive pressures from rivals like Johnson & Johnson's Tremfya, as noted by William Blair analyst Matt Phipps.
Regulatory Catalyst: Skyrizi Approval
Adding to the positive momentum, the FDA approved Skyrizi on Friday for children aged 6 and older with moderate-to-severe plaque psoriasis or active psoriatic arthritis. AbbVie's R&D head Roopal Thakkar highlighted it as the "first and only IL-23 inhibitor approved in the U.S." for younger pediatric patients under 40 kg, expanding the drug's market potential.
Broader Market Context
The rally was part of a broader healthcare sector uptick. The Health Care Select Sector SPDR Fund (NYSEARCA: XLV) rose 3.03% on Friday and gained 7.3% since June 18, while the S&P 500 (INDEXSP: .INX) fell 2.05% for the week and the Nasdaq Composite (INDEXNASDAQ: .IXIC) slid 4.7%. AbbVie, Eli Lilly (NYSE: LLY), and Johnson & Johnson (NYSE: JNJ) all hit record highs, with RBC Capital Markets analyst Trung Huynh citing strong positioning and pipeline deals.
Outlook and Key Dates
AbbVie is scheduled to report Q2 2026 earnings on July 31 before the market opens, with a conference call at 8 a.m. Central. The company also declared a quarterly dividend of $1.73 per share, payable August 14 to shareholders of record as of July 15. Traders are watching whether AbbVie can sustain levels above $250 and if the spread on Apogee's bid tightens ahead of the deal's close.
